findmyKOL
Clinical trialNCT06917885RecruitingPhase 1Interventional

CUE-102 in Recurrent Glioblastoma

SponsorDavid Reardon, MDEnrollment18GlioblastomaGlioma, MalignantRecurrent Glioblastoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    David A Reardon, MD
    Not, yet, recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    David A Reardon, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CUE-102
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jul 2025
Primary completion
31 Jan 2027
Completion
31 Jan 2028
Last update posted
5 Mar 2026
Registered enrollment
18
Registry id
NCT06917885
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.